The challenge of microvascular obstruction after primary percutaneous coronary intervention.

The challenge of microvascular obstruction after primary percutaneous coronary intervention. Curr Vasc Pharmacol. 2013 Mar 1;11(2):243-4 Authors: Niccoli G PMID: 23506501 [PubMed - in process]
Source: Current Vascular Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Vasc Pharmacol Source Type: research

Related Links:

Publication date: February 2020Source: IJC Heart &Vasculature, Volume 26Author(s): Sahar Tariq, Rajesh Kumar, Madiha Fatima, Tahir Saghir, Sobia Masood, Musa KarimAbstractObjectivesTo assess the frequency of early (acute and sub-acute) stent thrombosis (ST) after primary percutaneous coronary intervention (pPCI) and to identify its potential predictors.BackgroundST is a serious clinical event associated with a high mortality rate. A very limited data are available regarding the incidence rate of early ST after pPCI and its predictors, especially for Pakistani population.MethodsStudy included consecutive patients who un...
Source: IJC Heart and Vasculature - Category: Cardiology Source Type: research
This study showed that efficacy of 0.9 and 1.4 mm excimer laser catheter was equivalent in ELCA for AMI patients. If o ne takes into account lesion crossability, debulking effects, and the stunned platelets phenomenon, the 0.9 mm excimer laser catheter is sufficient for ELCA in AMI patients.
Source: Lasers in Medical Science - Category: Laser Surgery Source Type: research
AbstractDiabetes mellitus (DM) is an independent predictor of adverse outcomes in patients with coronary artery disease (CAD). We investigated the interaction between DM and high platelet reactivity (HPR) in determining long-term clinical outcomes after percutaneous coronary intervention (PCI). We enrolled 500 patients who were divided based on the presence of DM and HPR. Primary endpoint was the occurrence of major adverse clinical events (MACE) at 5  years. Patients with both DM and HPR showed the highest estimates of MACE (37.9%, log-rankp 
Source: Journal of Cardiovascular Translational Research - Category: Cardiology Source Type: research
ABSTRACTBackgroundTrends and clinical factors associated with prescribing choices for oral P2Y12 inhibitors (P2Y12-I) remain unknown for patients on chronic dialysis, i.e., with end-stage renal disease (ESRD).MethodsFrom 2011 –2014 U.S. Renal Data System registry, we identified 36,542 ESRD patients who received new prescriptions for P2Y12-I (median age 64.0 years and 54% males). Of the cohort, 93% were receiving hemodialysis and 7% on peritoneal dialysis. We analyzed trends and investigated clinical factors associated with specific P2Y12-I prescribed.ResultsClopidogrel was prescribed for 95%, prasugrel for 3%, and ti...
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research
The original version of this article unfortunately contained a mistake. The name of the author Keren-Lee Rozenfeld was rendered wrongly. The correct name is shown above.
Source: Clinical Research in Cardiology - Category: Cardiology Source Type: research
Coronary revascularization in patients with multi-vessel coronary artery disease (CAD) and diabetes has been an area of intense investigation. Diabetic patients currently comprise approximately 25% of all patients who undergo multi-vessel revascularization, either by percutaneous coronary intervention (PCI) or by coronary artery bypass grafting (CABG) surgery [1]. In comparison to non-diabetic patients, diabetes confers complex multi-vessel disease with more extensive and diffuse CAD [1,2]. Furthermore, diabetic patients experience worse outcomes than nondiabetic patients undergoing either CABG or PCI [1,2].
Source: International Journal of Cardiology - Category: Cardiology Authors: Tags: Editorial Source Type: research
Conditions:   Coronary Artery Disease;   Percutaneous Coronary Intervention Interventions:   Procedure: Percutaneous Coronary Intervention;   Device: Percutaneous Coronary Intervention using R-One assistance Sponsor:   Robocath Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 12 November 2019Source: Canadian Journal of CardiologyAuthor(s): Mohammed Shurrab, Asaf Danon, Sami Alnasser, Benedict Glover, Anna Kaoutskaia, Mark Henderson, David Newman, Eugene Crystal, Dennis KoAbstractBackgroundThe choice of antithrombotic therapy for atrial fibrillation (AF) patients who have an acute coronary syndrome (ACS) or have undergone percutaneous coronary intervention (PCI) is challenging. We aimed to assess outcomes between dual antithrombotic therapy with DOACs plus an antiplatelet agent (Dual therapy) in comparison to warfarin plus two antiplatelet agents (Triple therap...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
Vessel Fractional Flow Reserve (vFFR), a new angiography-derived method for the functional assessment of coronaries, was recently shown to have good correlation with invasive wire-derived FFR, when vFFR-specific image acquisition requirements were followed. We sought to investigate the feasibility of vFFR analysis and its correlation with FFR in the situation where angiography is completed in routine fashion, without intention for virtual analysis.
Source: International Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Insulin resistance (IR) is considered a pivotal risk factor for cardiometabolic diseases, and the triglyceride –glucose index (TyG index) has emerged as a reliable surrogate marker of IR. Although several recen...
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Tags: Original investigation Source Type: research
More News: Angioplasty | Coronary Angioplasty | Drugs & Pharmacology | Percutaneous Coronary Intervention